Full Breakdown
CDC Vaccine Recommendation Process Stalled Amid Political Turmoil
By Drooid · · How we work
Core Stalemate
The Centers for Disease Control and Prevention (CDC) has not issued a new recommendation for the recently approved mFlusiva influenza vaccine, despite the Food and Drug Administration’s full approval for adults ages 50-64. The agency’s website this month listed only the flu shots endorsed in the prior year, citing “legal uncertainties and inquiries.” Consequently, mFlusiva is absent from the CDC’s fall-season guidance, while medical societies are recommending it independently.
Background: Dismissal of the Advisory Committee and Legal Intervention
In the previous year, Health Secretary Robert F. Kennedy Jr., appointed by former President Donald Trump, dissolved the long-standing Advisory Committee on Immunization Practices (ACIP) and replaced it with a panel that included anti-vaccine members. A federal judge later ruled that Kennedy likely violated federal procedures, halted the new panel’s meetings, and suspended Kennedy’s order to cut the number of recommended childhood vaccine doses. The court decision was welcomed by many physicians and public-health groups as a pause to what they described as an “assault on vaccines.”
Effects on Specific Vaccines
- Respiratory syncytial virus (RSV) vaccine – ACIP had advised administration to pregnant women between September and January; medical societies now suggest offering it through early March to match a longer RSV season.
- HPV vaccine – A 2024 ACIP working group began reassessing the two-dose schedule, but the effort was derailed by the committee’s dismissal. Kennedy’s unilateral move to reduce the schedule to one dose was suspended by the judge’s order, leaving the recommendation in limbo.
- Vaccines for Children (VFC) program – After a summer of uncertainty, officials confirmed this week that orders for updated COVID-19 shots could be placed through VFC, though the CDC has not yet clarified coverage.
Official Statements & Responses
The CDC indicated that its unchanged guidance reflects unresolved legal questions. The FDA noted that mFlusiva’s approval followed a “tortuous” review process. A Department of Health and Human Services spokesperson declined to comment on any pending changes to federal vaccine-category definitions. The Governors Public Health Alliance warned that proposed federal changes could increase confusion and disease-outbreak risk for state residents.
Verbatim Quotes
- “We find ourselves at a point where even if credible evidence (for a new vaccine policy) has reached a tipping point, we don’t have an obvious mechanism that can formalize that change,” — Jason Schwartz, a Yale University health policy researcher
- “It’s Governors and their residents who bear the brunt of any increased disease outbreaks due to confusion related to hastily made federal changes,” — Angela Botticella, managing director of the Governors Public Health Alliance
